Interestingly, however, experimental and clinical evidence suggests that hyperactivation of the PI3K pathway promotes antiestrogen resistance in breast cancer [35], suggesting that simultaneous targeting of PI3K and ER pathways may be effective in ER+ breast cancer [36]. Here, PIK3CB is linked to breast cancer.